State Street SPDR S&P Biotech ETF
644 hedge funds and large institutions have $11.4B invested in State Street SPDR S&P Biotech ETF in 2021 Q1 according to their latest regulatory filings, with 75 funds opening new positions, 255 increasing their positions, 171 reducing their positions, and 78 closing their positions.
49% more repeat investments, than reductions
Existing positions increased: 255 | Existing positions reduced: 171
18% more funds holding in top 10
Funds holding in top 10: 17 → 20 (+3)
4% less first-time investments, than exits
New positions opened: 75 | Existing positions closed: 78
2% less funds holding
Funds holding: 654 → 644 (-10)
6% less capital invested
Capital invested by funds: $12.1B → $11.4B (-$694M)
19.81% less ownership
Funds ownership: 176.34% → 156.53% (-20%)
54% less call options, than puts
Call options by funds: $1.35B | Put options by funds: $2.93B
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$963M |
| 2 |
JP Morgan Chase
New York
|
+$872M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$240M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$139M |
| 5 |
SG Americas Securities
New York
|
+$75.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$769M |
| 2 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$708M |
| 3 |
Morgan Stanley
New York
|
-$311M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$299M |
| 5 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
-$241M |
XBI Hedge Fund Activity: Q1 2021 in Review
644 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2021, worth a combined $11.4B — down 5.8% from $12.1B a quarter earlier.
Sellers outnumbered buyers: 78 funds closed out of XBI and 75 opened new positions — a net loss of 3 holders — while 171 trimmed existing stakes and 255 added.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $963M. The largest seller was Goldman Sachs, cutting an estimated $769M.
- 644 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2021, down from 654 in Q4 2020.
- Funds reported $11.4B of State Street SPDR S&P Biotech ETF stock for Q1 2021, down 5.8% quarter-over-quarter.
- 75 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2021 and 78 closed out, a net change of -3 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2021 was BNP Paribas Financial Markets, an estimated $963M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2021 was Goldman Sachs, an estimated $769M sold.
Based on aggregated 13F filings for Q1 2021.